JNJ vs MDLN
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
JNJ presents a dichotomy between strong profitability and deteriorating fundamental health, evidenced by a weak Piotroski F-Score of 3/9. While the company maintains an impressive ROE of 35.03% and a consistent history of earnings beats, the current price of $237.96 trades at a significant premium to its Graham Number of $91.72. Growth remains robust on a YoY basis, but bearish insider sentiment and a very weak technical trend (10/100) suggest immediate headwinds. The stock is fundamentally sound in terms of earnings power but shows signs of operational inefficiency or declining quality in its deterministic health metrics.
MDLN exhibits strong fundamental health with a Piotroski F-Score of 7/9 and exceptional liquidity (Current Ratio 4.29), suggesting a stable operational baseline. However, the stock is currently trading at a premium to its Intrinsic Value ($42.18) and significantly above its Graham Number ($20.63). This valuation gap, combined with a starkly bearish technical trend and massive insider liquidation exceeding $3.5 billion, offsets the positive analyst consensus and revenue growth.
Compare Another Pair
Related Comparisons
JNJ vs MDLN: Head-to-Head Comparison
This page compares Johnson & Johnson (JNJ) and Medline Inc. (MDLN) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.